Valuation: Poltreg S.A.

Market Cap 142M 37.93M 32.98M 30.69M 28.18M 53.22M 3.62B 54.04M 362M 1.8B 142M 139M 6.05B P/E 2026 *
-4.57x
P/E 2027 * 6.27x
Enterprise Value 133M 35.61M 30.96M 28.81M 26.45M 49.96M 3.4B 50.73M 340M 1.69B 134M 131M 5.67B EV / Sales 2026 *
111x
EV / Sales 2027 * 0.98x
Free-Float
72.15%
Yield 2026 *
-
Yield 2027 * -
1 week+2.56%
1 month+28.34%
3 months+41.18%
6 months-6.98%
Current year-2.04%
1 week 21.3
Extreme 21.3
24
1 month 17.55
Extreme 17.55
25
Current year 16
Extreme 16
28.6
1 year 16
Extreme 16
32.7
3 years 16
Extreme 16
65
5 years 16
Extreme 16
73.9
10 years 16
Extreme 16
73.9
Manager TitleAgeSince
Chief Executive Officer - 2019-04-30
Chief Tech/Sci/R&D Officer - 2021-10-31
Corporate Officer/Principal - 2024-02-20
Director TitleAgeSince
Chairman - 2021-05-23
Director/Board Member 51 2021-05-20
Director/Board Member 43 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+2.56%-28.78%-63.08% 37.93M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.35%+1.20%+49.63%+84.79% 25.05B
Weighted average by Cap. -1.60%+2.03%+76.85%+128.07%

Financials

2026 *2027 *
Net sales 1.2M 321K 279K 259K 238K 450K 30.6M 457K 3.06M 15.24M 1.2M 1.18M 51.09M 116M 31.1M 27.03M 25.16M 23.1M 43.62M 2.97B 44.3M 297M 1.48B 117M 114M 4.96B
Net income -29.4M -7.85M -6.83M -6.36M -5.83M -11.02M -750M -11.19M -74.91M -373M -29.5M -28.85M -1.25B 24.2M 6.47M 5.62M 5.23M 4.8M 9.07M 617M 9.21M 61.66M 307M 24.28M 23.75M 1.03B
Net Debt -8.7M -2.32M -2.02M -1.88M -1.73M -3.26M -222M -3.31M -22.17M -110M -8.73M -8.54M -370M -28.4M -7.59M -6.6M -6.14M -5.64M -10.64M -724M -10.81M -72.36M -361M -28.49M -27.87M -1.21B
Logo Poltreg S.A.
Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.
Employees
37
Date Price Change Volume
26-07-31 PLN 24.00 -.--% 2,194
26-07-30 PLN 24.00 +4.80% 8,256
26-07-29 PLN 22.90 +3.62% 3,902
26-07-28 PLN 22.10 -2.64% 9,170
26-07-27 PLN 22.70 -2.99% 1,706

Quarterly revenue - Rate of surprise